Experts discuss the role of the coagulation casacade and the importance of the intricate balanace between thrombosis and hemostasis in normal liver homeostasis and in liver diseases such as DILI, MASH, and MASLD.
Experts provide information to help participants understand the current multidisciplinary approaches in identification of patients requiring consideration for early liver transplantation for severe alcohol-associated hepatitis and their clinical management. Topics include: prognostic models for predicting further decompensation versus recompensation; interpretation of phosphatidylethanol (PEth) testing; and approaches to reduce the likelihood of a return to alcohol use after liver transplantation.
This session comprises a critical discussion of the most notable and influential clinical research papers published in <em>HEPATOLOGY</em> in the past year by a team of associate editors from the journal <em>HEPATOLOGY</em>. Associate editors Yujin Hoshida, Jennifer Lai, and Manal Abdelmalek appraise the most cutting-edge, game-changing clinical science research literature. A panel discussion with the speakers, editor-in-chief Gregory Gores, and associate editor Jacqueline O’Leary highlights the clinical impact of selected papers and key challenges and opportunities in the field.
2025 AASLD Annual Business Meeting
Join us for AASLD’s Pride Reception, hosted by the LGBTQ+ Committee. This event offers a welcoming space for LGBTQ+ members and allies to connect, build community, and celebrate the values of inclusion and belonging within the hepatology field. Come share experiences and strengthen the spirit of connection that supports all members of our professional community.<br />
<br />
Sponsored by: Gilead Sciences<br />
Alumni and current awardees of the Emerging Liver Scholars program are welcome to join us for a meet-up in the Park.
This joint symposium from the Japan Society of Hepatology and AASLD addresses the important topic of alcohol-associated liver disease (ALD) care from an international perspective. Topics focus on ALD in Japan and in the United States. The first half of the session explores challenges and opportunities in the diagnosis and management of ALD. The second half discusses surgical and medical strategies for the management of alcohol-associated hepatitis. The session concludes with a disussion of future collaborative research opportunities and a question-and-answer period.
Cystic fibrosis hepatobiliary involvement (CFHBI) occurs in up to 90% of people with cystic fibrosis. Advanced cystic fibrosis liver disease is present in approximately 10% of people with cystic fibrosis. CFHBI is the third leading cause of morbidity and mortality in people with cystic fibrosis; early diagnosis and surveillance for disease progression are essential to optimize patient outcomes. Experts conducting this session review the current guidelines for monitoring CFHBI; the algorithm of care related to cystic fibrosis transmembrane conductance regulator protein modulator therapy hepatotoxicity; and the diagnositic and therapeutic options for managing advanced cystic fibrosis liver disease.
Experts lead participants in case-based discussions of patients hospitalized with acute-on-chronic liver failure (ACLF). Topics include the application of evidence-based strategies for the advanced clinical management of patients with ACLF and critical illness, and the role of liver transplantation in this patient population.
Presenters offer a comprehensive exploration of 3 key areas in hepatology: MASH, alcohol-associated liver disease, and primary biliary cholangitis (PBC). Attendees learn how to optimize patient selection for MASH therapies by utilizing clinical and diagnostic criteria, distinguishing MASH from cirrhosis, and incorporating fibrosis assessment to guide treatment strategies. Speakers also address the complexities of managing alcohol-associated liver disease, focusing on early recognition, evidence-based interventions, and overcoming long-term care challenges. Finally, participants gain insights into the diagnosis and treatment of PBC, including the use of current therapies and effective monitoring strategies to enhance patient outcomes.